

Solution | *Vaginal Microecological Modulation*

Lactocaseibacillus rhamnosus **LRa05**; *Lactobacillus crispatus* **LCr86**;
Limosilactobacillus reuteri **LR08**; *Lactiplantibacillus plantarum* **Lp90**;
pasteurized *Akkermansia muciniphila* **Akk11**; *Weizmannia coagulans* **BC99**

Key Excipients: Cranberry Powder; Vitamin C
Other Excipients: Inulin; Acacia Gum; Potato Starch

Functionality

- Optimizes vaginal microbiota structure
- Improves vaginal micro-ecological balance
- Promotes production of beneficial metabolites

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LRa05: ChiCTR2400080481
NCT06821789
NCT06901791

LCr86: NCT06830122

pAkk11: NCT06964932
NCT06964919

LRa05+LR08: NCT07013409

Lp90: NCT06987279


BC99: NCT06629441




Solution | **Vaginal Microecological Modulation**

Research Outcome

- Significantly enhanced microbial diversity and reshaped the vaginal micro-ecosystem structure
- Increased the relative abundance of beneficial *Lactobacillus* species and reestablishes dominant microbiota
- Effectively reduced *Candida* positivity rates and lowered the recurrence risk of fungal vaginosis.





Both the Simpson and Shannon indices significantly increased. Probiotics can remodel the structure of the vaginal microbiome.



The relative abundance of *Lactobacillus* in the placebo group increased from 82.9% to 85.8%, while in the LRa05 group it rose significantly from 56.3% to 71.3%

LRa05 effectively promoted the colonisation and dominance of beneficial *Lactobacillus* species.



Candida positivity rate was reduced by 33.4%.

Solution | *Improvement of Bacterial Vaginosis*

Lactobacillus rhamnosus **LRa05**; *Lactobacillus crispatus* **LCr86**;
Limosilactobacillus reuteri **LR08**; *Bifidobacterium animalis* subsp. *lactis* **BLa80**;
Bifidobacterium breve **BBr60**; *Weizmannia coagulans* **BC99**

Key Excipients: Cranberry Powder
Other Excipients: Inulin; Potato Starch

Functionality

- Addresses bacterial vaginosis effectively
- Improves Nugent score metrics
- Enhances vaginal cleanliness significantly

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LRa05: NCT06821789

LCr86: NCT06830122

LRa05+LR08: NCT07013409

BLa80: NCT06107049

BBr60: NCT06196892


BC99: NCT06629441



Research Outcome

- Significantly reduced Nugent score (diagnostic gold standard) , effectively improved the vaginal microenvironment and promoted the restoration of Nugent scores to the normal range.
- Improve vaginal cleanliness and promote the restoration of a healthy vaginal microbiome.
- Systematically promoted the restoration of microbial structure to a healthy state.


Promoted a healthy vaginal microbiome



Nugent scores were significantly reduced.

Effectively improves the vaginal microenvironment and promotes the restoration of Nugent scores to the normal range.

Improved vaginal cleanliness



Vaginal cleanliness scores were significant decreased.

Probiotic intervention can markedly improve vaginal cleanliness and promote the restoration of a healthy vaginal microbiome.

Solution | *Regulation of Glucose Metabolism During Pregnancy*

Lactocaseibacillus rhamnosus **LRa05**; *Lactobacillus crispatus* **LCr86**;
Limosilactobacillus reuteri **LR08**; *Bifidobacterium animalis* subsp. *lactis* **BLa80**;
Bifidobacterium longum subsp. *longum* **BL21**; *Bifidobacterium breve* **BBr60**;
Weizmannia coagulans **BC99**

Key Excipients: Vitamin D3; Vitamin K2; Ferrous Fumarate
Other Excipients: Fructo-oligosaccharides; Potato Starch

Functionality

- Significantly reduce fasting blood glucose and improves glycemic homeostasis
- Enriches beneficial sugar-metabolizing bacteria, such as *bifidobacteria*
- Inhibits the proliferation of metabolically harmful bacteria

7 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LRa05: NCT06901791

LCr86: NCT06830122

LRa05+LR08: NCT07013409

BLa80: ChiCTR2300073412

BL21: ChiCTR2300073299

BBr60: NCT06305650


BC99: NCT06629441




Research Outcome

- Significantly reduced fasting blood glucose levels
- Markedly enriched beneficial bacteria such as *Bifidobacteria*
- Effectively cleared harmful bacteria such as *Escherichia-Shigella*.

Significantly reduce fasting blood glucose



Effectively modulate gut microbiota



The relative abundance of *Bifidobacterium* significant increased.

The relative abundance of *Escherichia-Shigella* significant decrease.

Solution | *Improvement of vulvovaginal candidiasis*

Lactobacillus rhamnosus **LRa05**; *Lactobacillus crispatus* **LCr86**;
Limosilactobacillus reuteri **LR08**; *Pediococcus acidilactici* **PA53**;
Lactiplantibacillus plantarum **Lp90**; *Weizmannia coagulans* **BC99**

Key Excipients: Cranberry Powder

Other Excipients: Inulin; Fructo-oligosaccharides; Potato Starch

Functionality

- Precisely inhibits *Candida* colonization
- Rapidly restores vaginal cleanliness
- Repairs the mucosal barrier and alleviates vaginal inflammatory responses

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LRa05: ChiCTR2400080481

LCr86: NCT06830122

LRa05+LR08: NCT07013409

PA53: NCT06648590

Lp90: NCT06987279

BC99: NCT06629441






Research Outcome


- Reduced infections by pathogenic bacteria such as *Candida* and decreased leukocyte esterase positivity rates.
- Improved vaginal cleanliness and epithelial integrity, and repaired the mucosal barrier.

Reduces pathogen-associated biomarkers



Both *Candida* and leukocyte esterase positivity rates were decreased.

Significantly improves vaginal cleanliness and epithelial integrity



Vaginal cleanliness improved from Grade III-IV (infected state) to Grade I-II (healthy state). Vaginal epithelial exfoliation decreased and integrity increased.

Solution | ***Ovarian Function Protection and Support***

Lactocaseibacillus rhamnosus **LRa05**; *Lactobacillus crispatus* **LCr86**;
Limosilactobacillus reuteri **LR08**; *Bifidobacterium animalis* subsp. *lactis* **BLa80**;
Lactiplantibacillus plantarum **Lp90**; *Weizmannia coagulans* **BC99**

Key Excipients: Pomegranate Concentrate Powder;
Vitamin D3; Vitamin K2; Melon Powder
Other Excipients: Potato Starch

Functionality

- Restores leptin sensitivity and improves metabolic signaling
- Dual-target coordination of leptin and prolactin levels restores obesity-induced metabolic-reproductive endocrine dysregulation
- Protects normal ovarian physiological rhythm

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LRa05: NCT06821789

LCr86: NCT06830122

LRa05+LR08: NCT07013409

BLa80: NCT06107049


Lp90: NCT06987279

BC99: NCT06629441




Research Outcome

- Reduced leptin levels in obese women and help improve leptin sensitivity.
- Reduced prolactin levels in obese women and promoted the restoration of normal ovarian biological rhythm.



Reduced leptin levels in obese women. It indicated that probiotics help improve leptin sensitivity.



Significantly **reduced prolactin levels** in obese women.

It alleviated the suppression of the hypothalamic-pituitary-ovarian (HPO) axis through improvements in metabolism and the internal milieu.

Solution | ***Female Hormonal Balance Support***

Lactocaseibacillus rhamnosus **LRa05**; *Lactobacillus crispatus* **LCr86**;
Limosilactobacillus reuteri **LR08**; *Bifidobacterium breve* **BBr60**;
Lactiplantibacillus plantarum **Lp90**; *Weizmannia coagulans* **BC99**

Key Excipients: Saffron Extract

Other Excipients: Inulin; Fructo-oligosaccharides;
Potato Starch

Functionality

- Regulates the stress axis (ACTH) and improves the endocrine environment
- Restores leptin sensitivity and optimizes the gonadotropin microenvironment
- Promotes balance in the metabolic-stress-reproductive axis and systemically improves obesity-related endocrine disorders in women

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LRa05+LR08: NCT07013409

LCr86: NCT06830122

BBr60: NCT06305650,
NCT06196892

Lp90: NCT06987279



BC99: NCT06077383,
NCT06629441






Research Outcome

- Regulated hormone levels such as prolactin and adrenocorticotrophic hormone, and restored female reproductive endocrine rhythm.
- Regulated leptin levels, improve leptin sensitivity, and optimize the gonadotropin secretory microenvironment.



Significantly reduced prolactin and adrenocorticotrophic hormone (ACTH) levels in obese women.

It effectively alleviated the metabolic suppression of the hypothalamic-pituitary axis and restored female reproductive endocrine rhythm.



Reduced leptin levels in obese women.

It improved leptin sensitivity and optimized gonadotropin secretory microenvironment.

Solution | ***Female GLP-1 Regulation***

Lactocaseibacillus rhamnosus **LRa05**; *Lactobacillus crispatus* **LCr86**;
Limosilactobacillus reuteri **LR08**; *Bifidobacterium breve* **BBr60**;
Lactiplantibacillus plantarum **Lp90**; *Akkermansia muciniphila* **Akk11/pAkk11**;
Weizmannia coagulans **BC99**

Key Excipients: Astaxanthin Powder; Pomegranate Powder;
Green Tea Powder

Other Excipients: Inulin; Potato Starch

Functionality

- Modulates GLP-1 levels to help stabilize blood glucose balance
- Improves body composition parameters and reduces body fat percentage
- Modulates metabolism and improves energy efficiency

7 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LRa05+LR08: NCT07013409

LCr86: NCT06830122

BBr60: NCT06305650

Lp90: NCT06987279

Akk11: NCT06653101


pAkk11:
NCT06964932
NCT06964919

BC99:
NCT06307821,
NCT06629441




Solution | *Female GLP-1 Regulation*

The metabolic hormone GLP-1 was significantly elevated



Significantly increased glucagon-like peptide-1 (GLP-1) levels in obese women.

The satiety hormone peptide YY (PYY) was significantly increased



Significantly increased peptide YY (PYY) levels in obese women.

It indicated that probiotics enhanced physiological satiety signaling and may contributed to reduce energy intake.

Research Outcome

- Glucagon-like peptide-1 (GLP-1) levels were significantly elevated, improving energy metabolism through the "gut-endocrine axis".
- Peptide YY (PYY) levels were significantly elevated in obese women, enhancing physiological satiety signals and helping to reduce energy intake.

Solution | *Anxiety and Depressive Mood Regulation*

Lactocaseibacillus rhamnosus **LRa05**; *Lactobacillus crispatus* **LCr86**;
Limosilactobacillus reuteri **LR08**; *Bifidobacterium breve* **BBr60**;
Pediococcus acidilactici **PA53**; *Lactiplantibacillus plantarum* **Lp90**;
Weizmannia coagulans **BC99**

Key Excipients: Saffron Extract; Vitamin D3; Vitamin K2; Vitamin B6

Other Excipients: Inulin; Microcrystalline Cellulose

Functionality

- Specifically improves anxiety and depressive states in the obese female population
- Addresses concomitant emotional issues in obese women, achieving synergistic improvements in weight management and psychological health

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LRa05+LR08: NCT07013409

LCr86: NCT06830122

BBr60: NCT06196892

PA53: NCT06648590

Lp90: NCT06987279


BC99: NCT06629441



Research Outcome


- Anxiety self-rating scale scores were significantly reduced in obese women, effectively improving anxiety status.
- Depression self-rating scale scores were significantly reduced in obese women, effectively improving depressive status.

Alleviate anxiety symptoms



Significantly reduced anxiety self-rating scale scores in obese women.

Alleviate depressive symptoms



Significantly reduced depression self-rating scale scores in obese women.

Solution | *Sleep Quality Improvement*

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium breve **BBr60**; *Bifidobacterium longum* subsp. *longum* **BL21**;
Bifidobacterium adolescentis **BAC30**; *Bifidobacterium longum* subsp. *infantis* **BI45**;
Weizmannia coagulans **BC99**

Key Excipients: Melatonin; L-Theanine; Gamma-Aminobutyric Acid;
Magnolia Bark Powder; Ashwagandha Powder

Other Excipients: Inulin; Fructo-oligosaccharides; Potato Starch

Functionality

- Significantly improves anxiety and depressive mood
- Shortens sleep onset time and enhances sleep quality
- Increases life quality and satisfaction

7 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: NCT06107049

LRa05: NCT06821789

BBr60: NCT06196892

BC99: NCT06629441

BLa80+BL21+BBr60+BAC30+BI45: NCT06847919




Research Outcome

- Probiotic intervention shortened sleep onset time, improved sleep quality, and promoted better sleep.
- Both HAMA and HAMD scores decreased, helping alleviate anxiety and depressive mood.

DOI: 10.1038/s41598-025-95208-2
DOI: 10.3390/nu17193087

8 weeks


Improves sleep quality



Probiotic intervention group exhibited an average 22-minute reduction in sleep onset time and a 1.5-point decrease in sleep quality scores.

8 weeks

Alleviates anxiety and depression



Probiotic intervention significantly alleviated anxiety and depressive symptoms in adults, **with HAMA and HAMD scores reduced by 12.0 and 9.7 points respectively.**

Solution | ***Attention and Behavioral Regulation***

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium breve **BBr60**; *Pediococcus acidilactici* **PA53**;
Lactiplantibacillus plantarum **Lp90**; *Weizmannia coagulans* **BC99**

Key Excipients: Bacopa monnieri Extract; Vitamin B6; Sialic Acid
Other Excipients: Fructo-oligosaccharides; Potato Starch

Functionality

- Alleviates symptoms of attention deficit
- Reduces manifestations of hyperactivity and impulsivity
- Improves executive function and emotional regulation

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80+LRa05: NCT06348121

BBr60: NCT06196892

PA53: NCT06648590

Lp90: NCT06987279

BC99: NCT06676111




Research Outcome

- Significantly improved cognitive and executive functions, aiding in the enhancement of emotional regulation, behavioral management, and cognitive modulation abilities.
- Improved core ADHD symptoms such as attention deficit, hyperactivity, and impulsive behaviors.

DOI: 10.1002/mnfr.70234


Improve cognitive and executive function



After 8 weeks of probiotic intervention, subjects showed **notable improvements in cognitive and executive function**.

Their capacities for **emotional regulation, behavioral management, and cognitive modulation** were also significantly boosted.

Improve typical ADHD symptoms



Following an 8-week probiotic intervention, subjects demonstrated a **significant reduction in core ADHD symptoms**.

Specifically, their **attention deficits** were improved, and **hyperactivity and impulsive behaviors** were effectively alleviated.

Solution | *Anxiety and Depressive Mood Regulation*

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium breve **BBr60**; *Pediococcus acidilactici* **PA53**;
Limosilactobacillus reuteri **LR08**; *Weizmannia coagulans* **BC99**

Key Excipients: Ashwagandha Powder (*Withania somnifera*);
L-Theanine; Gamma-Aminobutyric Acid (GABA); Resveratrol
Other Excipients: Inulin; Potato Starch

Functionality

- Alleviates symptoms associated with depression and anxiety.
- Modulates inflammatory cytokine levels and improves immune-inflammatory status.
- Regulates neurotransmitter levels and supports neurofunctional balance.

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80+LRa05: NCT06216587

BBr60: NCT06196892

BC99: NCT06629441

LRa05: NCT06821789

PA53: NCT06648590

LRa05+LR08: NCT07013409




Research Outcome

- SAS scores decreased with the duration of probiotic intervention, aiding in the alleviation of anxiety symptoms.
- Significantly increased γ -GABA levels and reduced nitric oxide (NO) content, positively influence anxiety and depressive mood by modulating neurotransmitter and related signaling molecule levels.


DOI: 10.3390/nu17193087
DOI: 10.1163/18762891-bja00083

Reduce anxiety and depression levels



Probiotic intervention induced a **significant, progressive SAS score decrease** vs. the placebo group (no significant changes at any time point).

Regulate neurotransmitter levels



Following 8 weeks of probiotic intervention, a **significant increase in γ -GABA levels** and a **notable reduction in nitric oxide (NO) content** were observed.

Solution | ***Stress State Alleviation***

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactocaseibacillus rhamnosus* **LRa05**;
Bifidobacterium breve **BBr60**; *Pediococcus acidilactici* **PA53**;
Bifidobacterium longum subsp. *longum* **BL21**; *Weizmannia coagulans* **BC99**

Key Excipients: Ashwagandha Powder (*Withania somnifera*);
L-Theanine; Vitamin B6; Coenzyme Q10

Other Excipients: Fructo-oligosaccharides; Potato Starch

Functionality

- Supports emotional balance and psychological well-being under stress
- Helps regulate inflammation associated with physiological stress responses
- Supports stress-related brain–gut communication and signaling pathways

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80+LRa05: NCT06216587

LRa05: NCT06821789

BBr60: NCT06196892

PA53: NCT06648590

BL21: NCT06544278

BC99: NCT06629441






Research Outcome


- Positive Emotion Scale scores increased significantly, improved positive emotional states and alleviate stress levels.
- The constipation improvement rate increased, effectively alleviated stress-related functional gastrointestinal symptoms, improved intestinal motility and bowel function.

Improve emotional state and alleviates stress levels



After 8-week probiotic intervention, **positive Emotion Scale scores increased** significantly, with a **4.92-point rise** vs. baseline.

Improve Functional gastrointestinal symptoms related to stress



The constipation improvement rate after 8-week probiotic intervention was **significantly higher by 41.8% (53.8% vs. 12%)**.

Solution | ***Weight Management and Metabolic Balance***

Bifidobacterium breve **BBr60**; *Lactocaseibacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Lactiplantibacillus plantarum* **Lp90**;
Limosilactobacillus reuteri **LR08**; *Weizmannia coagulans* **BC99**

Key Excipients: Green Tea Powder; Blood Orange Concentrate Powder
Other Excipients: Inulin; Acacia Gum; Potato Starch

Functionality

- Improves energy metabolism efficiency
- Supports weight management
- Aids in fat reduction

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BBr60:NCT06305650

BL21:NCT06140641

LRa05+LR08:NCT07013409

LRa05:NCT06821789

Lp90:NCT06987279

BC99:NCT06077383






Research Outcome


- Modulated gut microecology and key metabolic pathways to enhance energy metabolism efficiency
- Maintained the homeostasis of blood glucose, blood lipids and inflammation-related indicators.
- Modulated the metabolic level of GLP-1 to support long-term metabolic health
- Enhanced the body's metabolic adaptability and reduces the risk of metabolic disturbances

DOI: 10.3390/ijms252010871
DOI: 10.3390/nu16233990


12 weeks




The probiotic group exhibited greater weight loss.




The probiotic group showed a more significant decrease in fat mass and increase in fat-free mass.



12 weeks



The probiotic group showed **significantly higher GLP-1 levels**.



BBr60 intervention group exhibited **lower fasting blood glucose (FBG) levels** (Week 12: 5.26 ± 0.57 vs 5.69 ± 0.86 , between-group $p = 0.0381$), **improving glycemic homeostasis**.

*GLP-1 (Glucagon-like peptide-1): A gut-derived incretin hormone secreted by intestinal L-cells, which plays a key role in blood glucose regulation, energy balance, and metabolic control.

Solution | ***Sports Nutrition and Physical Performance Support***



Bifidobacterium breve **BBr60**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Bifidobacterium animalis* subsp. *lactis* **BLa80**;
Akkermansia muciniphila **Akk11/pAkk11**; *Weizmannia coagulans* **BC99**

Key Excipients: Vitamin B6; Vitamin K2;
Black Pepper Extract
Other Excipients: Resistant Dextrin;
Fructo-oligosaccharides; Potato Starch

Functionality

- Enhances nutrient metabolism efficiency
- Supports physical performance and endurance enhancement
- Promotes post-exercise recovery

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BBr60:
NCT06305650
NCT06196892

BL21: NCT06140641

Akk11: NCT06653101

BC99: NCT06307821

LRa05:
ChiCTR2300073308
NCT06901791

BLa80: ChiCTR2300073412

pAkk11:
NCT06964932
NCT06964919






Research Outcome

- Optimized gut micro-ecology and nutrient utilization to support efficient energy metabolism during exercise
- Enhanced metabolic adaptation, fatigue resistance, and protection against exercise-induced metabolic and oxidative stress
- Supported muscle function, and efficient post-exercise recovery to improve endurance performance


DOI: [10.3390/nu16233990](https://doi.org/10.3390/nu16233990)

12 weeks



BC99 group showed significantly **increased digestive enzyme activity**, suggesting that BC99 may **enhance physical performance and muscle synthesis** by improving protein digestion and absorption efficiency.

12 weeks



Athletes in BC99 intervention group **increased times of repetitions** at 80% of one-rep max (1RM) by **1.3 times** in the bench press and by **2.1 times** in the squat.

Solution | ***Liver Protection and Metabolic Support***

Bifidobacterium breve **BBr60**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**;
Bifidobacterium animalis subsp. *lactis* **BLa80**; *Weizmannia coagulans* **BC179**;
Akkermansia muciniphila **Akk11/pAkk11**; *Weizmannia coagulans* **BC99**

Key Excipients: Turmeric Powder; Milk Thistle Extract
Other Excipients: Fructo-oligosaccharides; Inulin;
Potato Starch

Functionality

- Accelerates ethanol and acetaldehyde metabolism
- Modulates liver function-related indicators
- Reduces oxidative stress damage

7 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80+LRa05+BC99+BC179: ChiCTR2400082180

BL21: NCT06544278

BC99: NCT06607562

Akk11: NCT06780007

BLa80+LRa05: NCT06216587

BBr60: NCT06196892

BC179: NCT06899620


pAkk11:
NCT06964932
NCT06964919



Research Outcome


- Balanced blood glucose, blood lipids, and inflammatory markers
- Supported evidence-based weight management by enhancing metabolic adaptability
- Modulated gut micro-ecology and liver-metabolism pathways to improve energy and lipid metabolism efficiency
- Promoted liver function and overall metabolic health, reducing the risk of metabolic disorders

30 days




Probiotic significantly **increased the activity of ADH and ALDH enzymes** after alcohol consumption, thereby accelerating the metabolism of ethanol and acetaldehyde. It also significantly **reduced breath and blood alcohol concentrations at 15 and 30 minutes after drinking**.

30 days



BC179 intervention significantly **reduced MDA levels after alcohol consumption** ($p < 0.001$).

2 months



After two months of intervention, **all four liver function markers — ALT, AST, TBil, and γ-GT — showed significant decreases**. Notably, the rates of abnormal AST and γ-GT levels, which were 34.78% and 30.43% respectively before intervention, dropped to 0%.

Solution | *Anti-Aging and Functional Maintenance*

Bifidobacterium breve **BBr60**; *Lactocaseibacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**;
Bifidobacterium animalis subsp. *lactis* **BLa80**; *Weizmannia coagulans* **BC99**;
Lactobacillus acidophilus **LA85**; *Lactocaseibacillus paracasei* **LC86**;
Pediococcus acidilactici **PA53**; *Lactiplantibacillus plantarum* **Lp05**

Key Excipients: Haematococcus pluvialis Powder;
Pomegranate Concentrate Powder; Resveratrol

Other Excipients: Inulin; Potato Starch

Functionality

- Regulates oxidative stress status
- Improves physical fitness
- Promotes nutrient absorption and muscle synthesis

9 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80+LRa05+BC99+BL21+LA85+LC86+BBr60+PA53+Lp05:
NCT06781814
NCT07025798






Research Outcome

- Modulated oxidative stress status and reduced oxidative damage
- Promoted nutrient absorption and supported muscle protein synthesis
- Significantly enhanced physical performance and overall fitness

DOI: 10.3389/fimmu.2025.1654724
DOI: 10.3390/nu16233990

8 weeks


Improve oxidative stress



BC99 intervention group showed a **significant increase in the antioxidant marker glutathione (GSH)** and a **significant decrease in the oxidative damage marker malondialdehyde (MDA)**.

8 weeks

Enhance strength capacity



BC99 intervention group demonstrated **significant improvements in strength endurance performance**. The times of repetitions at 80% of one-repetition maximum (1RM) increased by 1.3 repetitions (+12.9%) in the bench press and by 2.1 (+19.3%) in the squat.

Solution | ***Glycemic Homeostasis Regulation***

Bifidobacterium breve **BBr60**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Bifidobacterium animalis* subsp. *lactis* **BLa80**;
pasteurized *Akkermansia muciniphila* **pAkk11**; *Weizmannia coagulans* **BC99**

Key Excipients: Green Tea Powder; Edible
Mushroom Concentrate Powder (*Agaricus bisporus*)
Other Excipients: Inulin; Acacia Gum; Potato Starch

Functionality

- Improves insulin sensitivity
- Significantly reduces fasting blood glucose
- Improves lipid and glucose metabolism

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LRa05: ChiCTR2300073308
NCT06901791

BL21: ChiCTR2300073299

BLa80+LRa05+BBr60: NCT06440486

BC99: NCT06307821

BBr60: NCT06305650

BLa80: ChiCTR2300073412

pAkk11: NCT06964932
NCT06964919




Research Outcome

- Significantly reduced serum insulin, fasting blood glucose and glycated hemoglobin levels
- Improved insulin sensitivity and long-term glycemic control in Type II diabetes patients
- Enhanced lipid metabolism, lowering total cholesterol and triglycerides, boosted beneficial LPL activity to reduce atherosclerosis risk
- Supported healthy glucose metabolic homeostasis and overall metabolic balance


12 weeks

Blood glucose level Improvement in patients with Type II diabetes



12 weeks

Lipid Metabolism and Cardiovascular Risk Improvement



Solution | **GLP-1 Functional Modulation**

Bifidobacterium breve **BBr60**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**;
Lactiplantibacillus plantarum **Lp90**; *Limosilactobacillus reuteri* **LR08**;
Akkermansia muciniphila **Akk11/pAkk11**; *Weizmannia coagulans* **BC99**

Key Excipients: Green Tea Powder; Vitamin B6; Black Pepper Extract (*Piper nigrum*)

Other Excipients: Inulin; Acacia Gum; Potato Starch

Functionality

- Enhances GLP-1 levels to regulate appetite and glucose control
- Optimizes lipid metabolism to support cardiovascular health
- Balances overall metabolic functions and activates intrinsic health-maintaining mechanisms

7 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LRa05+LR08: NCT07013409

BBr60: NCT06305650

BL21: ChiCTR2300073299

Lp90: NCT06987279

pAkk11: NCT06964932, NCT06964919

Akk11: NCT06653101


BC99: NCT06307821



Research Outcome

- Increased GLP-1 levels to regulate appetite and glucose metabolism
- Improved lipid metabolism to support cardiovascular health
- Balanced metabolic functions and activated intrinsic health-regulating pathways

Increase GLP-1 Levels



pAkk11 group demonstrated a **significant increase in GLP-1** after 12 weeks of intervention.

Akk11 group **increased plasma GLP-1 levels to 10.7 pmol/L**, compared with 9.6 pmol/L in the placebo group.

Solution | ***Relief of Alcohol-Related Discomfort***

Bifidobacterium breve **BBr60**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Bifidobacterium animalis* subsp. *lactis* **BLa80**;
Weizmannia coagulans **BC179**; *Weizmannia coagulans* **BC99**

Key Excipients: Rice Bran Fatty Alcohols; Milk Thistle Extract;
Other Excipients: Inulin; Potato Starch

Functionality

- Accelerates alcohol and acetaldehyde metabolism
- Rapidly reduces blood alcohol concentration
- Improves short-term cognitive performance

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80+LRa05+BC99+BC179: ChiCTR2400082180

BL21: NCT06544278

BC99: NCT06607562

BBr60: NCT06196892

BC179: NCT06899620




Research Outcome


- Accelerated alcohol and acetaldehyde breakdown to support faster recovery of alertness
- Reduced blood and breath alcohol levels to shorten systemic alcohol exposure
- Improved cognitive respond following alcohol intake
- Alleviated metabolic burden of alcohol metabolism to support a more comfortable post-drinking experience

DOI : 10.3390/antiox14091038.

A




B




Accelerate alcohol and
acetaldehyde
metabolism

Support rapid reduction of blood and breath alcohol levels

C




D



Support short-term
cognitive performance
following alcohol intake

E



BC179 group showed **a significant reduction in hangover symptom scores**, along with markedly **increased serum ADH and ALDH levels** and a **significant decrease in blood alcohol concentration**. In addition, the BC179 group exhibited **significant reductions in serum alkaline phosphatase and plasma endotoxin levels**.

Solution | ***Lipid Homeostasis Regulation***

Bifidobacterium breve **BBr60**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Weizmannia coagulans* **BC179**;
Akkermansia muciniphila **Akk11/pAkk11**; *Weizmannia coagulans* **BC99**

Key Excipients: Turmeric Powder; Natto Powder
Other Excipients: Inulin; Potato Starch

Functionality

- Modulates blood lipid levels
- Reduces total cholesterol and triglyceride levels effectively
- Contributes to the maintenance of cardiovascular health

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LRa05+BC99+BC179: ChiCTR2400082180

BL21: NCT06140641

pAkk11: NCT06964932, NCT06964919

BBr60: NCT06305650, NCT06196892


Akk11: NCT06780007



Research Outcome

- Increased GLP-1 levels, contributing to the regulation of appetite and glycemic control
- Improved lipid metabolism, supporting cardiovascular and cerebrovascular health
- Through coordinated hormonal and metabolic regulation, probiotics promoted overall metabolic balance and activated intrinsic health-regulating mechanisms

Effective Regulation of Blood Lipid Levels



Solution | ***Body Management and Muscle Support***

Bifidobacterium breve **BBr60**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Bifidobacterium animalis* subsp. *lactis* **BLa80**;
Lactiplantibacillus plantarum **Lp90**; *Limosilactobacillus reuteri* **LR08**;
Weizmannia coagulans **BC99**

Key Excipients: Vitamin B6; Vitamin K2; Black Pepper Extract;
Green Tea Powder; Blood Orange Concentrate Powder
Other Excipients: Inulin; Fructo-oligosaccharides; Potato Starch

Functionality

- Modulates blood glucose levels
- Reduces in glycated hemoglobin (HbA1c) and insulin levels
- Supports the maintenance of glucose metabolic health

7 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LRa05: NCT06821789

BBr60: NCT06305650

Lp90: NCT06987279

BC99: NCT06307821

BL21: NCT06140641




BLa80: ChiCTR2300073412

LR08: NCT06875362



Research Outcome

- Improved insulin utilization efficiency, supporting glucose metabolism and glycemic control
- Enhanced metabolic flexibility, promoting fat oxidation and efficient energy utilization in skeletal muscle.
- Multidimensional metabolic support contributing to coordinated management of body fat and lean mass
- Improved glycemic regulation, including reduced blood glucose, glycated hemoglobin (HbA1c), and insulin levels



Solution | ***Uric Acid Metabolism Regulation***

Bifidobacterium breve **BBr60**; *Lacticaseibacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Bifidobacterium animalis* subsp. *lactis* **BLa80**;
Lactobacillus acidophilus **LA85**; *Lacticaseibacillus paracasei* **LC86**;
Pediococcus acidilactici **PA53**; *Lactiplantibacillus plantarum* **Lp05**;
Streptococcus salivarius subsp. *thermophilus* **ST36**; *Weizmannia coagulans* **BC99**

Excipients: Inulin;Fructo-oligosaccharides; Potato Starch

Functionality

- Modulates immune factor levels
- Reduces inflammation markers
- Supports overall balance of immune and inflammatory responses

10 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80+LRa05+BC99+BL21+LA85+LC86+BBr60+PA53+Lp05:
NCT06781814, NCT07025798


ST36:
NCT06779994




Research Outcome

- Modulated immune factor levels to enhance immune homeostasis
- Reduced systemic inflammation and inflammatory markers
- Supported balanced immune and inflammatory responses, promoting overall immune regulation

Modulation of Immune Factor Levels



Reduction of Inflammation Levels





Solution | ***Blood Pressure Homeostasis Support***

Bifidobacterium breve **BBr60**; *Lactcaseibacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Lactiplantibacillus plantarum* **Lp90**;
Bifidobacterium animalis subsp. *lactis* **BLa36**; *Lactcaseibacillus casei* **LC89**;
Pediococcus acidilactici **CCFM7902**; *Bifidobacterium adolescentis* **BAC30**;
Weizmannia coagulans **BC99**

Key Excipients: Edible Mushroom Concentrate Powder (Agaricus bisporus)
Other Excipients: Inulin;Fructo-oligosaccharides; Potato Starch

Functionality

- Improves blood lipid levels
- Reduces inflammation levels
- Modulates gut microbiota composition
- Increases short-chain fatty acid (SCFA) levels

9 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES


LRa05: ChiCTR2300073308, NCT06901791

BC99: NCT06629441

BL21+BBr60+Lp90+BLa36+LC89+CCFM7902+BAC30:
NCT06873412

Research Outcome

- Improved blood lipid profiles and supported blood pressure homeostasis, contributing to overall cardiometabolic health
- Promoted glucose regulation, lowered fasting blood glucose, HbA1c and insulin levels
- Reduced systemic inflammation and regulated immune factor levels, maintaining a balanced immune and inflammatory state
- Gut microbiota composition was modulated and short-chain fatty acid (SCFA) production increased



After 6 weeks of probiotic treatment, **HDL-C was significantly increased** and **FBG was significantly decreased** compared with placebo.

Solution | *Integrated Management of Hypertension, Hyperglycemia, and Hyperlipidemia*

Bifidobacterium breve **BBr60**; *Lactobacillus rhamnosus* **LRa05**;

Bifidobacterium longum subsp. *longum* **BL21**; *Bifidobacterium animalis* subsp. *lactis* **BLa80**;

Limosilactobacillus reuteri **LR08**; *Weizmannia coagulans* **BC99**

Key Excipients: Turmeric Powder; Vitamin D3

Other Excipients: Inulin; Fructo-oligosaccharides; Potato Starch

Functionality

- Modulates lipid metabolism to support blood lipid control
- Improves gastrointestinal health to enhance metabolic regulation.
- Balances immune factors to reduce metabolic inflammation and improve metabolic resilience
- Regulates gut microbiota composition

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: ChiCTR2300073412

BBr60: NCT06305650, NCT06196892

BC99: NCT06307821


LRa05:
ChiCTR2300073308, NCT06901791

LR08: ChiCTR2300073299



Research Outcome

- Regulated lipid metabolism and supported blood lipid homeostasis
- Improved gastrointestinal health and optimized digestion and nutrient absorption
- Modulated gut microbiota composition, contributing to integrated management of cardiometabolic risk factors
- Balanced immune factor levels, enhancing metabolic resilience



Compared with placebo, probiotic intervention **significantly reduced participants' uric acid levels**. In addition, the intervention markedly **increased high-density lipoprotein (HDL) levels**.

Solution | *Improvement of Constipation and Bowel Movement Difficulty*

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactobacillus rhamnosus* **LRa05**;
Lactobacillus acidophilus **LA85**; *Bifidobacterium longum* subsp. *longum* **BL21**;
Bifidobacterium breve **BBr60**; *Bifidobacterium adolescentis* **BAC30**;
Bifidobacterium longum subsp. *infantis* **BI45**; *Weizmannia coagulans* **BC99**

Excipients: Inulin; Fructo-oligosaccharides; Resistant Dextrin; Potato Starch

Functionality

- Promotes intestinal motility and increases bowel movement frequency
- Alleviates constipation symptoms
- Elevates levels of neurotransmitters and hormones associated with gastrointestinal motility

8 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: NCT05980988
NCT04798417

LRa05: NCT06103240
ChiCTR2300072220
ChiCTR2100053700

BLa80+BL21+BBr60+BAC30+BI45: NCT06847919

BC99: ChiCTR2200065493
NCT06637397




Solution | **Improvement of Constipation and Bowel Movement Difficulty****Research Outcome**

- Significantly increased Bristol Stool Scale scores and bowel movement frequency
- Improves constipation-related symptoms such as dry/hard stools, bloating, and abdominal pain.
- Elevated levels of neurotransmitters and hormones associated with gastrointestinal motility


8 weeks

Promote intestinal peristalsis and alleviates difficulty in defecation



In constipated patients, a **significant increase of 50.8%** in the neurotransmitter serotonin and a **48.6% rise** in the hormone motilin.

Increase bowel movement frequency and improves constipation symptoms



Probiotic intervention **significantly increased the spontaneous bowel movement score (by 0.87 points)** and **significantly reduced the constipation symptom assessment score (by 3.29 points)** in constipated patients.

Solution | *Diarrhea Symptom Relief*

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactocaseibacillus rhamnosus* **LRa05**;
Lactobacillus acidophilus **LA85**; *Bifidobacterium longum* subsp. *longum* **BL21**;
Bifidobacterium breve **BBr60**; *Weizmannia coagulans* **BC99**

Key Excipients: Yeast Beta-Glucan

Other Excipients: Fructo-oligosaccharides; Acacia Gum;
Resistant Dextrin; Potato Starch

Functionality

- Significantly increases the efficacy rate of diarrhea treatment
- Alleviates diarrhea symptoms
- Improves stool consistency

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: ChiCTR2100053699
NCT05662514

LA85: NCT05974657

BBr60: NCT06305650
NCT06196892

LRa05: ChiCTR2100053700

BL21: ChiCTR2300069881

BC99: NCT06629441





Research Outcome

- Significantly increased the efficacy rate of diarrhea treatment.
- Alleviated diarrhea symptoms in ADD patients, with a significant reduction in the proportion of patients experiencing diarrhea.
- Promoted the restoration of normal bowel movements, transitioning stool consistency from acute watery diarrhea back to a normal form.

7 days


Significantly increases the efficacy rate of diarrhea treatment



Probiotic intervention effectively improved diarrhea symptoms, with a 34.5% increase in the significant efficacy rate, a 4.6% rise in the effective rate, and a **39.1% improvement in the overall efficacy rate**.

2 weeks

The proportion of patients with diarrhea is significantly reduced



Probiotic intervention alleviates diarrhea symptoms in ADD patients. The proportion of patients experiencing diarrhea is significantly reduced (17.2% vs 0%).

Solution | ***Gastric Protection and Helicobacter pylori Management Support***

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Bifidobacterium breve* **BBr60**;
Lactiplantibacillus plantarum **Lp05**; *Weizmannia coagulans* **BC99**

Key Excipients: L-Glutamine

Other excipients: Fructo-oligosaccharides; Resistant Dextrin; Potato Starch

Functionality

- Significantly increases the eradication rate of *Helicobacter pylori*
- Alleviates gastrointestinal-related adverse reactions caused by *Helicobacter pylori* treatment
- Promotes the restoration of gut microbiota diversity

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: NCT05662514

BL21: NCT06544278

Lp05: ChiCTR2400079562

LRa05: ChiCTR2300072220

BC99: ChiCTR2300073499

BBr60: NCT06305650
NCT06196892




Research Outcome

- Significantly increased the eradication rate of *Helicobacter pylori*.
- Significantly alleviated gastrointestinal-related adverse reactions induced by *Helicobacter pylori* treatment.
- Promoted the restoration of immune homeostasis.
- Modulates the gut microbiota, helps restore microbial diversity, increases beneficial bacteria, and reduces harmful bacteria, improves gastric function.

4 weeks


Significantly enhances the eradication rate of *Helicobacter pylori*



Probiotic intervention increased the *Helicobacter pylori* eradication rate in patients by 13.98%.

4 weeks

Significantly alleviates gastrointestinal-related adverse reactions during *Helicobacter pylori* treatment



Increased the efficacy rates for alleviating abdominal pain by 55.31%, bloating by 31.43%, and acid reflux by 44% in patients. These results indicate that probiotics effectively reduce the occurrence of adverse reactions—such as abdominal pain, bloating, and acid reflux—during *Helicobacter pylori* treatment.

Solution | **Regulation of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)**

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Pediococcus acidilactici* **PA53**;
Bifidobacterium bifidum **BBi32**; *Weizmannia coagulans* **BC99**

Excipients: Inulin; Fructo-oligosaccharides; Acacia Gum;
Potato Starch

Functionality

- Increases daily bowel movement frequency
- Improves stool consistency
- Alleviation of IBS symptoms with improvements in quality of life

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: NCT04798417

LRa05: NCT06103240, ChiCTR2300072220, ChiCTR2100053700

BL21: ChiCTR2300069881, NCT06140641,
ChiCTR2300073299, NCT06544278

PA53: NCT06761443, NCT06648590

BBi32: NCT06886711

BC99: ChiCTR2200065493, NCT06637397




Research Outcome

- Improved bowel movement frequency and stool consistency
- Alleviated the burden of IBS-related symptoms
- Supported gut functional health and enhanced quality of life


DOI: [10.1007/s00394-024-03398-8](https://doi.org/10.1007/s00394-024-03398-8)

Average daily bowel movement frequency



Probiotic intervention significantly **increased the average daily bowel movement frequency**.

IBS Symptom Assessment



BLa80 intervention significantly **reduced the severity of IBS symptoms**, improving symptoms such as abdominal pain, bloating, and bowel habit irregularities.

Solution | ***Gastrointestinal Motility Regulation***

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium breve **BBr60**; *Pediococcus acidilactici* **PA53**;
Streptococcus salivarius subsp. *thermophilus* **ST36**; *Weizmannia coagulans* **BC99**

Key Excipients: Protease

Other Excipients: Inulin; Fructo-oligosaccharides; Resistant Dextrin;
Potato Starch

Functionality

- Improves constipation-related symptoms and quality of life
- Upregulates of neurotransmitters involved in gastrointestinal motility
- Attenuates inflammatory status with modulation of metabolic pathways associated with gastrointestinal motility

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: NCT04798417

BBr60: NCT06196892

ST36: NCT06779994

LRa05: ChiCTR2300072220

PA53: NCT06761443, NCT06648590


BC99: ChiCTR2200065493, NCT06637397, NCT06307821



Research Outcome


- Improved bowel function and enhanced intestinal transit
- Modulated multiple pathways involved in GI motility—including neurotransmitter signaling, inflammatory mediators, and metabolic pathways
- Promoted the restoration of gastrointestinal motor function and improves gut health and quality of life

Promote gastrointestinal peristalsis



8 weeks of Intervention significantly increased serum levels of serotonin (5-hydroxytryptamine, 5-HT) and motilin.

Increase bowel movement frequency



8 weeks of probiotic intervention resulted in a **significant increase in spontaneous bowel movements**, accompanied by marked **improvements in constipation-related symptoms**, including hard stools, difficulty in defecation, bloating, and abdominal pain.

Solution | ***Support for Chemo- and Radiotherapy-Associated Intestinal Injury***

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactobacillus rhamnosus* **LRa05**;
Lactobacillus acidophilus **LA85**; *Bifidobacterium longum* subsp. *longum* **BL21**;
Bifidobacterium longum subsp. *infantis* **BI45**; *Weizmannia coagulans* **BC99**

Excipients: Inulin; Potato Starch

Functionality

- Reduces risk of developing moderate-to-severe radiation enteritis
- Attenuates diarrhea severity
- Modulates gut microbiota composition

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: ChiCTR2100053699, NCT05662514

LRa05: ChiCTR2100053700

LA85: NCT05974657

BL21: ChiCTR2300069881

BI45: NCT06863415


BC99: ChiCTR2200065493, NCT06637397, NCT06307821



Research Outcome


- Mitigated chemotherapy- and radiotherapy-associated intestinal injury
- Modulated gut microbiota composition
- Reduced the risk of moderate-to-severe radiation enteritis and alleviated diarrhea
- Supported the stabilization and recovery of intestinal function in patients undergoing chemoradiotherapy

Attenuation of intestinal injury severity



The incidence of acute radiation-induced intestinal injury of grade ≥ 2 (ARIII) was significantly reduced from 65.0% to 27.2%.

Reduction in the incidence of diarrhea



The incidence of diarrhea decreased from 57.0% to 29.5%.

Solution | *Gut Microbiota Homeostasis Regulation*

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Bifidobacterium breve* **BBr60**;
Akkermansia muciniphila **Akk11/pAkk11**; *Weizmannia coagulans* **BC99**

Excipients: Inulin; Fructo-oligosaccharides; Acacia Gum;
Resistant Dextrin; Galacto-oligosaccharides; Potato Starch

Functionality

- Improve constipation-related symptoms and quality of life
- Upregulate of neurotransmitters involved in gastrointestinal motility
- Attenuate inflammatory status with modulation of metabolic pathways associated with gastrointestinal motility

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: ChiCTR2100053699, NCT05662514,
NCT06107049, NCT06103253, ChiCTR2300073412,
ChiCTR2300074956, NCT06412042

BL21: ChiCTR2300069881, NCT06140641,
ChiCTR2300073299, NCT06544278

Akk11: NCT06653101; **pAkk11:** NCT06964932,
NCT06964919

LRa05: NCT06103240, ChiCTR2300072220, ChiCTR2100053700,
ChiCTR2300073308, NCT06699537, NCT06901791

BBr60: NCT06305650, NCT06196892


BC99: ChiCTR2200065493, ChiCTR2300073499, NCT06607562,
NCT06077383, NCT06629441, NCT06676111, NCT06885346,
NCT06885632



Research Outcome


- Promoted stable colonization of beneficial bacteria
- Inhibited overgrowth of opportunistic pathogenic bacteria
- Enhanced gut microbiota diversity
- Maintained gut microbial homeostasis and overall functional balance

Increase in the relative abundance of beneficial bacteria



After 12 weeks of intervention, the probiotic group exhibited significantly **higher relative abundances of beneficial bacteria compared with placebo**, including *Faecalibacterium* (10.4% vs. 4.8%) and *Bifidobacterium* (7.3% vs. 3.0%).

Decrease in the relative abundance of potentially pathogenic bacteria



After 12 weeks of intervention, the probiotic group showed significantly **lower relative abundances of potential pathogenic bacteria compared with placebo**, including *Clostridium* (0.5% vs. 1.8%) and *Escherichia/Shigella* (3.4% vs. 6.4%).

Solution | *Immune Defense Support*

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactocaseibacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Limosilactobacillus reuteri* **LR08**
Bifidobacterium breve **BBr60**; *Bifidobacterium longum* subsp. *infantis* **BI45**;
Weizmannia coagulans **BC99**

Key Excipients: Inactive edible yeast; Zinc Gluconate

Other Excipients: Fructo-oligosaccharides; Galacto-oligosaccharides; Maltodextrin

Functionality

- Promotes immune homeostasis by supporting balanced immune regulation
- Enhances mucosal barrier integrity and supports healthy antimicrobial defense
- Modulates inflammatory responses to reduce excessive inflammation
- Supports overall immune balance and controlled immune recovery

7 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80:

ChiCTR2100053699
ChiCTR2300074956
NCT06412042

BL21: NCT06544278

LR08: NCT06875362

BBr60:

NCT06305650
NCT06196892

BI45: NCT06863415

BC99:

ChiCTR2200065493
NCT06607562
NCT06637397
NCT06629441
NCT06680102
NCT06676111
NCT06885346
NCT06885632

LRa05:

ChiCTR2300072220
ChiCTR2100053700
NCT05989295
ChiCTR2400080481
NCT06699537
NCT06821789
NCT06901791




Research Outcome

- Significantly reduced antimicrobial peptide LL-37 levels, elevated calprotectin levels, improved mucosal barrier function
- Elevated anti-inflammatory factor levels, reduced pro-inflammatory factor levels, effectively modulated systemic inflammatory status
- Maintained stable levels of key inflammatory factors, promoted the restoration of immune homeostasis, and supported balanced immune regulation

8 weeks


Modulation of antimicrobial peptide LL-37 and calprotectin levels



LR08 intervention significantly elevated serum immunoglobulin IgA and IgM levels while **reducing antimicrobial peptide LL-37** and increasing calprotectin content, enhancing mucosal immunity and modulating innate immune responses.

8 weeks

Reduction in inflammatory levels in patients with constipation



BC99 intervention significantly **reduced patients' pro-inflammatory factor IL-6** levels ($p < 0.05$) while elevating anti-inflammatory factors IL-4 and IL-10 ($p < 0.01$).

Solution | *Symptom Relief for Adult Allergic Rhinitis*

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium breve **BBr60**; *Pediococcus acidilactici* **PA53**;
Akkermansia muciniphila **Akk11/pAkk11**; *Weizmannia coagulans* **BC99**

Key Excipients: Yeast Beta-Glucan; Chaga Mushroom Powder
Other Excipients: Fructo-oligosaccharides; Galacto-oligosaccharides; Potato Starch

Functionality

- Alleviates allergic rhinitis symptoms effectively
- Regulates immune factor levels to improve immune homeostasis
- Promotes the secretion of short-chain fatty acids to strengthen anti-inflammatory capabilities

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80:
ChiCTR2100053699
ChiCTR2300074956
NCT06412042

BBr60: NCT06196892

Akk11: NCT06653101
pAkk11: NCT06964932, NCT06964919

LRa05: NCT06699537

PA53: NCT06761443, NCT06648590



BC99: NCT06680102, NCT06885346



Research Outcome




- Alleviated allergic rhinitis and enhanced respiratory comfort
- Anti-allergic and anti-inflammatory effects through immune regulation to improve immune homeostasis
- Optimized gut microbiota ecology to support microbiota health
- Promoted short-chain fatty acid production to strengthen gut barrier and anti-inflammatory capabilities

8 weeks



Participants showed **significantly reduced scores** for rhinitis symptoms (nasal congestion, itching, sneezing, runny nose) and associated symptoms (post-nasal drip, sudden tearing, nasal and eye itching, nasal and palatal pain, headache).

8 weeks



Participants showed a **significant decrease in serum immunoglobulin IgE** and **pro-inflammatory IL-5 levels**, along with a **significant increase in anti-inflammatory IL-10 levels**.

Solution | *Symptom Relief for Pediatric Allergic Rhinitis*

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Bifidobacterium breve* **BBr60**;
Bifidobacterium longum subsp. *infantis* **BI45**; *Weizmannia coagulans* **BC99**

Key Excipients: Inactive edible yeast

Other Excipients: Fructo-oligosaccharides; Galacto-oligosaccharides; Maltodextrin

Functionality

- Significantly alleviates allergic rhinitis symptoms
- Markedly reduces nasal and ocular discomfort, enhancing overall quality of life
- Effectively lowers inflammation-related cytokine levels, supporting immune regulation and reducing inflammation

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80:
ChiCTR2100053699
ChiCTR2300074956
NCT06412042

BBr60: NCT06305650, NCT06196892

BI45: NCT06863415

LRa05: NCT06699537

BL21: NCT06544278


BC99: NCT06676111, NCT06885632






Research Outcome


- Significantly alleviated allergic rhinitis symptoms
- Markedly reduced nasal and ocular discomfort, effectively improved quality of life
- Lowered inflammation-related cytokine levels and alleviate inflammatory responses, scientifically validated immune regulation effects




8 weeks



The total rhinitis symptom score **decreased by 1.39 points**. Associated symptom score decreased by 3 points.



8 weeks



Compared to baseline, **participants' quality of life significantly improved**.

Participants' **serum IL-4 levels were significantly reduced**.

Solution | *Support for Pediatric Atopic Dermatitis Modulation*

Bifidobacterium animalis subsp. *lactis* **BLa80**; *Lactobacillus rhamnosus* **LRa05**;
Bifidobacterium longum subsp. *longum* **BL21**; *Limosilactobacillus reuteri* **LR08**;
Akkermansia muciniphila **Akk11/pAkk11**; *Weizmannia coagulans* **BC99**

Excipients: Fructo-oligosaccharides;
Galacto-oligosaccharides; Maltodextrin

Functionality

- Alleviates eczema discomfort and protects sensitive skin
- Enhances skin hydration and strengthens the natural skin barrier
- Reduces rash incidence, supporting overall skin health and management

6 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: ChiCTR2300074956, NCT06412042

LRa05: NCT05989295

BL21: NCT06544278

LR08: NCT06875362

Akk11: NCT06653101

BC99: NCT06676111, NCT06885632



pAkk11: NCT06964932, NCT06964919







Research Outcome

- Reduced eczema symptoms and alleviated discomfort in children with mild atopic dermatitis
- Increased skin hydration levels, strengthening the skin's natural barrier
- Significantly reduced the incidence of rashes, effectively preventing and improving allergic skin conditions in infants and young children



LRa05 intervention **reduced eczema symptoms** in children with mild atopic dermatitis.

LRa05 intervention **increased skin hydration levels** in children.



Probiotics significantly **reduced the incidence of rashes** in infants and young children.

Solution | ***Gut Immune Support in Infants and Young Children***

Bifidobacterium animalis subsp. *lactis* **BLa80**;

Lactacaseibacillus rhamnosus **LRa05**

Excipients: Fructo-oligosaccharides; Galacto-oligosaccharides;
Resistant Dextrin; 2'-Fucosyllactose; Maltodextrin

Functionality

- Enhances immune defense capacity
- Enriches functional genes associated with immune regulation in the gut microbiome
- Increases gut microbial species diversity

2 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: ChiCTR2100053699
ChiCTR2300074956
NCT06412042

LRa05: ChiCTR2100053700




Research Outcome

- Significantly increased antimicrobial peptide LL-37 and human β -defensin-2
- Enhanced local immune defense in response to infection or inflammatory stimuli

DOI: [10.1038/s41430-024-01428-6](https://doi.org/10.1038/s41430-024-01428-6)
DOI: <https://doi.org/10.3345/cep.2025.01256>

7 days



Probiotic intervention significantly **elevated** levels of antimicrobial peptide LL-37 and human β -defensin-2 (hBD-2).

Solution | ***Eczema Risk Management in Infants and Young Children***

Bifidobacterium animalis subsp. *lactis* **BLa80**;
Lactocaseibacillus rhamnosus **LRa05**

Excipients: Fructo-oligosaccharides;
Resistant Dextrin; Maltodextrin

Functionality

- Significantly improves the eczema remission rate
- Reduces the frequency of eczema episodes
- Improves skin hydration

2 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: ChiCTR2300074956
NCT06412042

LRa05: NCT05989295




Research Outcome


- Significantly reduced the frequency of eczema episodes, and increased the eczema improvement rate.
- significantly improves skin hydration.

DOI: <https://doi.org/10.3345/cep.2025.01256>

12 weeks



Probiotic intervention **significantly reduced the average number of eczema episodes** compared with the breastfed group in infants aged 15 days to 36 months.



Probiotic intervention **significantly increased the eczema improvement rate.**

Solution | **Neurodevelopmental Support in Infants and Children**

Bifidobacterium animalis subsp. *lactis* **BLa80**;

Lactobacillus rhamnosus **LRa05**

Key Excipients: Vitamin D3; Zinc Gluconate

Other Excipients: Fructo-oligosaccharides;

Resistant Dextrin; Maltodextrin

Functionality

- Supports the development of motor function and coordination
- Facilitates language acquisition and cognitive processing
- Promotes healthy neurodevelopment in infants and young children

2 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80: NCT06412042



BLa80+LRa05: NCT06348121



Research Outcome

- Promoted development of motor skills, enhanced language learning abilities
- Supported healthy neurodevelopment in infants and young children
- Provided safe, science-based micro-ecological nutritional support for early growth and development

DOI: [10.3345/cep.2025.01256](https://doi.org/10.3345/cep.2025.01256)



Improvements in motor skill development were observed only following probiotic intervention. In addition, **language acquisition abilities were enhanced**.

Solution | *Respiratory Health and Immune Support*

Bifidobacterium animalis subsp. *lactis* **BLa80**;
Lactaseibacillus rhamnosus **LRa05**

Excipients: Fructo-oligosaccharides;
Resistant Dextrin; Maltodextrin

Functionality

- Improves constipation-related symptoms and quality of life
- Upregulates of neurotransmitters involved in gastrointestinal motility
- Attenuates inflammatory status with modulation of metabolic pathways associated with gastrointestinal motility

2 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

BLa80+LRa05: NCT06348095




Research Outcome

- Significant reduction in acute respiratory infections and eczema incidence
- Enhanced gut-derived immune defense by activating the gut-lung immune axis
- Provided a safe and effective microbiota-based approach to support respiratory immune health


DOI: [10.3345/cep.2025.01256](https://doi.org/10.3345/cep.2025.01256)

Significant Reduction in the Incidence of Common Pediatric Diseases



Probiotic intervention significantly **decreased the incidence of acute upper respiratory infections and eczema** in infants.

Enhancement of Immune Function in Infants and Young Children



Probiotic Intervention **significantly elevated levels of LL-37 and HBD-2** in the intestinal mucosa.

Solution | ***Gut Microbiota Modulation in C-section Delivered Infants***

Bifidobacterium animalis subsp. *lactis* **BLa80**;
Lactaseibacillus rhamnosus **LRa05**

Excipients: Fructo-oligosaccharides; Galacto-oligosaccharides;
Resistant Dextrin; Maltodextrin

Functionality

- Improve constipation-related symptoms and quality of life

2 Strains

Optional Excipients

Powder / Capsule Form





Solution | ***Oral Microbiota and Local Immune Regulation***

Ligilactobacillus salivarius **LS97**;
Lactobacillus acidophilus **LA85**;
Lactocaseibacillus paracasei **LC86**

Functionality

- Improves oral microbiota composition
- Strengthens oral immune defense
- Improves the oral microenvironment

3 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LS97+LA85+LC86: ChiCTR2300074088




Research Outcome

- Enhanced oral immune defense and significantly increase salivary IgA levels.
- Supported a healthy oral microenvironment and increases the levels of beneficial short-chain fatty acids (such as acetate and propionate).
- Promoted oral microbiota balance and enhanced microbial diversity, and reduced the population of certain potentially harmful bacteria.

8 weeks


Elevated oral salivary IgA and acetic acid levels



Intervention group showed **significantly higher levels of salivary IgA and beneficial short-chain fatty acids.**

8 weeks

Improved Oral microbial diversity



The oral microbiota **α-diversity** in the probiotic group **remained higher**, and the overall microbiota structure did not undergo significant alteration.

Solution | ***Periodontal Health Improvement Support***

Ligilactobacillus salivarius **LS97**;

Lactobacillus acidophilus **LA85**;

Lactocaseibacillus paracasei **LC86**

Functionality

- Enhances oral mucosal immune defense
- Reduces probing pocket depth
- Improves gingival bleeding and inflammation

3 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES

LS97+LA85+LC86: ChiCTR2300074108







Research Outcome

- Significantly increased salivary IgA levels in individuals with periodontitis
- Reduced probing pocket depth and lowers bleeding on probing index
- Dual effects on immune defense and tissue inflammation, providing a scientific, microbiota-based solution for periodontal health

Enhanced immune function



Alleviation of periodontal inflammation symptoms



Probiotic intervention significantly **increased salivary IgA levels**, **reduced probing pocket depth (PD)** and **bleeding on probing (BOP) values**.

Solution | ***Oral Freshness Maintenance***



Ligilactobacillus salivarius **LS97**;

Lactobacillus acidophilus **LA85**;

Lactocaseibacillus paracasei **LC86**

Functionality

- Decomposes the source of bad breath gases, directly reducing the production of odor-causing substances
- Alleviates oral inflammation
- Dual pathway freshening mechanism, reducing inflammatory halitosis

3 Strains

Optional Excipients

Powder / Capsule Form

Scientific Support

CLINICAL STUDIES


LS97+LA85+LC86: ChiCTR2400080658



Research Outcome


- Significantly reduced oral volatile sulfur compounds (VSC), addressing bad breath at its source
- Effectively lowered gingival inflammatory markers and improved overall oral health
- Dual mechanism of action ensures long-lasting fresh breath maintenance
- Provided an innovative solution based on oral microbiota balance

Improve bad breath



Probiotic intervention significantly reduced VSC levels in patients.

Reduced gingival inflammation



Patients' levels of gingival TNF-α and IL-1β were significantly reduced.